Back to results
US 2023/0248780 A1Published application
Cell-based gene therapy for neurodegenerative diseases
AssigneeALSaTECH, Inc.
InventorsClaude NICOLAU, Claudine KIEDA, Reynald THINARD, Ruth GREFERATH, Melanie CHEVALIER
Life of this patent
Estimating the term…
Abstract
The present invention relates, in part, to cell-based gene therapies, including those targeting, by way of non-limiting example, TDP43 and Aβ aggregates, for the use in neurodegenerative disorders, including without limitation Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease, respectively.
Claims24
-99. (canceled)
An antibody or antigen binding fragment thereof directed against TDP43 comprising:
- (i) a variable heavy domain (VH) comprising:
- complementarity-determining region (CDR) 1 having the amino acid sequence of SEQ ID NO:
- 19,
- CDR2 having the amino acid sequence of SEQ ID NO:
- 20, and
- CDR3 having the amino acid sequence of SEQ ID NO:
- 21;
- and
- (ii) a variable light domain (VL) comprising:
- CDR1 having the amino acid sequence of SEQ ID NO:
- 22,
- CDR2 having the amino acid sequence of SEQ ID NO:
- 23, and
- CDR3 having the amino acid sequence of SEQ ID NO:
- 24.
12 more elements
(canceled)
(canceled)
112-117. (canceled)
Dependencies are inferred from the claim text.